Literature DB >> 26870344

Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice.

Fang-Fang Gao1, Jia-Wei Lv2, Ying Wang1, Rong Fan3, Qun Li4, Zun Zhang1, Lei Wei1.   

Abstract

Clinically, hepatotoxicity is an inevitable side effect during long-term endocrinotherapy in breast cancer patients. Various studies have reported the specific mechanism and protective methods for this long-term hepatotoxicity, however, the short-term influences of tamoxifen (TAM) on hepatocytes remain to be elucidated. The previous study investigated TAM-induced liver injury at the early stage of endocrine treatment. Mice were assigned into 2 groups: The experiment group was administrated with intraperitoneal (i.p.) injection of 6 mg/kg/day TAM for 2 weeks, and the control group was administrated with i.p. injection of physiological saline of the same dose. Body weights in each group were detected every day, and alanine aminotransferase and aspartate aminotransferase levels were measured every 3 days. Small pieces of the liver tissues were obtained and processed for protein extraction, biochemical detection and histopathological analysis 2 weeks later. The results indicated that TAM decreased the mice body weights. Morphologically, with the treatment of TAM for only 2 weeks, at the microscopic and ultrastructural levels the structure of hepatic cords became blurred in sections of the regions, although the lobules of the liver remained visible. Partially, hepatic cells were swelled in spherical shapes. Nuclei appeared to be pyknotic and exhibited uneven chromatin distribution. In addition, it was observed in the transmission electron microscopy analysis that nuclei became pyknotic and unevenly distributed. The majority of the nuclei were endowed with distinct heterochromatin and thick nucleoli. The mitochondrial cristae became vague and disorganized. Finally, western blotting was used and detected a significant increase of the caspase-3 level in the liver tissues. In conclusion, the experiments elucidated that TAM (6 mg/kg/day) would cause hepatotoxicity at the early stage of endocrine treatment in mice, and the underlying mechanism was involved with hepatocyte apoptosis.

Entities:  

Keywords:  breast cancer; hepatotoxicity; short-term treatment; tamoxifen

Year:  2015        PMID: 26870344      PMCID: PMC4726841          DOI: 10.3892/br.2015.536

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  28 in total

Review 1.  A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Authors:  Nahla E El-Ashmawy; Rania M Khalil
Journal:  Tumour Biol       Date:  2013-12-12

2.  Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; Nikolaos P Polyzos; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

3.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective.

Authors:  Hesham A El-Beshbishy
Journal:  J Biochem Mol Biol       Date:  2005-05-31

6.  Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.

Authors:  Y Murata; Y Ogawa; T Saibara; A Nishioka; Y Fujiwara; M Fukumoto; T Inomata; H Enzan; S Onishi; S Yoshida
Journal:  Oncol Rep       Date:  2000 Nov-Dec       Impact factor: 3.906

Review 7.  Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.

Authors:  Geniey Yang; Somaira Nowsheen; Khaled Aziz; Alexandros G Georgakilas
Journal:  Pharmacol Ther       Date:  2013-05-24       Impact factor: 12.310

Review 8.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

Authors:  V Craig Jordan; Bert W O'Malley
Journal:  J Clin Oncol       Date:  2007-09-24       Impact factor: 44.544

9.  Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.

Authors:  I N White; F de Matteis; A Davies; L L Smith; C Crofton-Sleigh; S Venitt; A Hewer; D H Phillips
Journal:  Carcinogenesis       Date:  1992-12       Impact factor: 4.944

10.  Protective role of thymoquinone against liver damage induced by tamoxifen in female rats.

Authors:  Ghada M Suddek
Journal:  Can J Physiol Pharmacol       Date:  2014-05-26       Impact factor: 2.273

View more
  10 in total

1.  Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.

Authors:  Michael S Sidorov; Matthew C Judson; Hyojin Kim; Marie Rougie; Alejandra I Ferrer; Viktoriya D Nikolova; Natallia V Riddick; Sheryl S Moy; Benjamin D Philpot
Journal:  J Neurosci       Date:  2018-02-05       Impact factor: 6.167

2.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

3.  Synergistic Effects of Lauryl Gallate and Tamoxifen on Human Breast Cancer Cell.

Authors:  Keihan Ghatreh Samani; Effat Farrokhi; Aliye Tabatabaee; Narges Jalilian; Mahbube Jafari
Journal:  Iran J Public Health       Date:  2020-07       Impact factor: 1.429

4.  Xiaotan Jieyu Prescription Alleviates Breast Precancerous Lesions through PI3K/Akt Signaling Pathway.

Authors:  Jing Zhao; Tao Pang; Jian-Peng Jiao; Bin Wang; Xuan Liu; Li-Juan Xiu; Da-Zhi Sun; Xiao-Qiang Yue; Chao-Qin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-12       Impact factor: 2.629

5.  Attenuating the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase-Sex-Determining Region Y-Box 9 Axis Promotes Liver Progenitor Cell-Mediated Liver Regeneration in Zebrafish.

Authors:  Juhoon So; Minwook Kim; Seung-Hoon Lee; Sungjin Ko; Daniel A Lee; Hyewon Park; Mizuki Azuma; Michael J Parsons; David Prober; Donghun Shin
Journal:  Hepatology       Date:  2021-04       Impact factor: 17.425

6.  Chlorogenic acid abates oxido-inflammatory and apoptotic responses in the liver and kidney of Tamoxifen-treated rats.

Authors:  Solomon E Owumi; Joseph K Olusola; Uche O Arunsi; Adegboyega K Oyelere
Journal:  Toxicol Res (Camb)       Date:  2021-02-13       Impact factor: 3.524

7.  Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-Characterized Cyclopia Extract.

Authors:  Omolola R Oyenihi; Annadie Krygsman; Nicolette Verhoog; Dalene de Beer; Michael J Saayman; Thys M Mouton; Ann Louw
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

8.  Mindfulness-Based Stress Reduction on breast cancer symptoms: systematic review and meta-analysis.

Authors:  Flavia Del Castanhel; Rafaela Liberali
Journal:  Einstein (Sao Paulo)       Date:  2018-12-06

9.  Specificity and off-target effects of AAV8-TBG viral vectors for the manipulation of hepatocellular gene expression in mice.

Authors:  Christos Kiourtis; Ania Wilczynska; Colin Nixon; William Clark; Stephanie May; Thomas G Bird
Journal:  Biol Open       Date:  2021-09-22       Impact factor: 2.422

10.  Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines.

Authors:  Dominik Wupperfeld; Gert Fricker; Béatrice Bois De Fer; Larissa Frank; Annika Wehrle; Branko Popovic
Journal:  Lipids Health Dis       Date:  2022-09-24       Impact factor: 4.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.